Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 10, 2026

Moxie Raises $25M Series C to Bring Clinical-Grade Operating Infrastructure to Independent Aesthetic Practices

View original at globenewswire.com
Moxie Raises $25M Series C to Bring Clinical-Grade Operating Infrastructure to Independent Aesthetic Practices BROOKLYN, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Moxie, the clinical-grade operating system for aesthetic medicine, today announced a $25 million Series C funding round led by Viewpoint Ventures, with partic…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Moxie helps aesthetic entrepreneurs save 25+ hours each week

    60% confidence
  • Moxie let me stop being a firefighter and start being a CEO. The financial clarity alone changed how I make decisions. Moxie has helped me gain control over my business so my business doesn't have control over me.

    60% confidence
  • The aesthetic practices that thrive long-term aren't the loudest or the busiest. They're the most disciplined. We built Moxie to give independent practice owners the same caliber of operating infrastructure that was previously only available to those backed by institutional capital.

    60% confidence
  • Aesthetic medicine has grown faster than its infrastructure. We have world-class clinicians running practices on spreadsheets and workarounds — and that's a risk to patients, to margins, and to the long-term credibility of the specialty. Clinically-led growth isn't a marketing phrase. It's the operating discipline that separates practices that scale from practices that collapse under their own weight.

    60% confidence
  • Moxie-supported practices save up to 55% on injectables, devices, and supplies with top-tier pharmaceutical, skincare, and manufacturing companies

    60% confidence
  • Moxie-supported practices grow 60% faster than the industry average

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com